Abstracts tagged "interstitial lung disease and scleroderma"

Abstract Number: 1115 • ACR/ARHP Annual Meeting 2018
In Vivo Assessment of Prevention of Lung Fibrosis Using the Pan-PPAR Agonist Lanifibranor in the Tβriiδk-Fib Mouse Model of Systemic Sclerosis
Emma C. Derrett-Smith^1,2, Shiwen Xu¹, David Abraham³, Olivier Lacombe⁴, Pierre Broqua⁴, Jean-Louis Junien⁴, Irena Konstantinova⁵ and Christopher P. Denton⁶, ¹Division of Medicine, University College London, London, United Kingdom, ²Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴Inventiva, DAIX, France, ⁵Inventiva, Daix, France, ⁶University College London, London, United Kingdom
Background/Purpose: The TbRIIDk-fib transgenic (TG) mouse model of scleroderma carries a fibroblast-specific transforming growth factor β (TGFβ) receptor II mutation resulting in balanced up-regulation of…
Abstract Number: 829 • ACR/ARHP Annual Meeting 2016
High Level of Chemokine CCL2 Is Associated with Lung Fibrosis Progression and Reduced Survival in Two Independent Systemic Sclerosis Cohorts
Anna Hoffmann-Vold¹, Richard Huyen², Elizabeth R. Volkmann², Oyvind Midtvedt¹, Vyacheslav Palchevskiy², May Brit Lund³, Torhild Garen¹, Trond Mogens Aalokken⁴, Anders Heiervang Tennøe¹, Stephen Samuel Weigt², Mike Shino², Rajan Saggar⁵, David Ross², Joseph Lynch III², Thor Ueland⁶, Michael Fishbein⁷, Pål Aukrust⁸, Øyvind Molberg¹ and John A Belperio², ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁴Radiology, Oslo University Hospital, Oslo, Norway, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Research, Oslo University Hospital, Oslo, Norway, ⁷Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, ⁸Research Intitute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: Markers for early identification of progressive interstitial lung disease (ILD) in systemic sclerosis (SSc) are in demand. The proto-typical inflammatory chemokine CCL2 has been linked…
Abstract Number: 838 • ACR/ARHP Annual Meeting 2016
Esophageal Dysmotility and Interstitial Lung Disease in Patients with Scleroderma: A Retrospective Study
Shweta Kishore¹, Santhanam Lakshminarayanan¹, Chia-Ling Kuo² and Ranadeep Mandhadi¹, ¹Division of Rheumatology, University of Connecticut, Farmington, CT, ²Department of Community Medicine and Health Care, University of Connecticut, Farmington, CT
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease with pulmonary involvement seen in 75% of patients and esophageal involvement in 90% of the patients.…
Abstract Number: 2966 • ACR/ARHP Annual Meeting 2015
Pulmonary Involvement in Systemic Sclerosis at Initial Presentation: A Single Center Experience
Ranadeep Mandhadi¹ and Santhanam Lakshminarayanan², ¹Division of Rheumatology, The University of Connecticut Health Center, Farmington, CT, ²Division of Rheumatology, University of Connecticut Health Center, Farmington, CT
Background/Purpose: Systemic Sclerosis (SSc) is a rare heterogeneous autoimmune connective tissue disease.Pulmonary involvement is the major cause of mortality and morbidity in Systemic sclerosis. The…
Abstract Number: 2984 • ACR/ARHP Annual Meeting 2015
Scleroderma Bronchoalveolar Lavage Fluid Thrombin Activity: Correlation with Pulmonary Function
Merrideth Ashley Morris¹, Tanjina Akter², Paul Nietert³, Galina S. Bogatkevich² and Richard Silver⁴, ¹Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³Division of Public Health Science, Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Multiple lines of evidence identify thrombin as an important mediator of lung fibrosis in systemic sclerosis (SSc). In addition to demonstrating dramatically high levels…
Abstract Number: 1679 • ACR/ARHP Annual Meeting 2014
A Double Blind Randomized Control Trial of Oral Tadalafil in Interstitial Lung Disease of Scleroderma
Jyoti Parida¹, Alok Nath², Zafar Neyaz³ and Vikas Agarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Radiodiagnosis, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose We conducted a single center double-blind, randomized, placebo-controlled trial to determine the effects of oral Tadalafil on lung function and health-related symptoms in patients…